RxDoctor Payments Data

Rui Cerejo, DO

Rheumatology · Palm Beach Gardens, FLNPI 1013917277

Payments from drug & device makers

$11,005in general payments, 2019–2025

Across 582 payments — averaging $18.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Amgen$2K
  • Novartis$2K
  • AbbVie$1K
  • UCB, Inc.$846
  • E.r. Squibb & Sons, L.L.C.$601
  • plus $2K from 9 others

What the payments were for

  • Consulting fees$1752%
  • Food & beverage$10,77698%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson104$2,243
Amgen(2 entities)97$2,151
Novartis115$1,716
AbbVie61$1,352
UCB, Inc.48$846
E.r. Squibb & Sons, L.L.C.29$601
Pfizer39$580
AstraZeneca24$492
GSK14$305
Genentech USA, Inc.25$221
Sanofi6$174
Lilly USA, LLC11$147
Bristol Myers Squibb6$119
Radius Health, Inc.2$35
Boehringer Ingelheim1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,005 in reported general payments places this provider in the 50th percentile of 453 rheumatology providers in Florida.

See all rheumatology providers in Florida

Medicare billing

Part B allowed, 2024
$3,723,349
Medicare patients
999
Services billed
272,563

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept46$403,497
Xeljanz XrTofacitinib Citrate45$279,018
EnbrelEtanercept20$232,665
Enbrel MiniEtanercept11$180,017
Humira(Cf) PenAdalimumab17$166,458
Orencia ClickjectAbatacept22$138,690
Taltz SyringeIxekizumab13$90,364
Cosentyx Sensoready (2 Pens)Secukinumab12$80,084
RinvoqUpadacitinib12$73,904
BenlystaBelimumab13$63,277
OtezlaApremilast11$61,721
Hydroxychloroquine Sulfate358$16,407
MethotrexateMethotrexate Sodium334$9,217
Celecoxib98$5,154
Duloxetine Hcl197$4,794

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenEnbrel, Otezla$2,151$294,38731 claims
AbbVieRinvoq$1,352$73,90412 claims
GSKBenlysta$305$63,27713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 453 rheumatology providers in Florida.

Other rheumatology in Palm Beach Gardens

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →